DEPLOY

Buying guide

LocusBot vs Hugo RAS in 2026

Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.

Key differences

  • LocusBot has more capabilities independently verified as autonomous (1 vs 0).
  • LocusBot has more verified real-world deployments (6 vs 3).
Attribute
ManufacturerLocus RoboticsMedtronic
Form factoramrsurgical
Maturitycommercialcommercial
Autonomy1 verified autonomous◐ not independently verified
Availabilityinternal-onlyenterpriseinternal-onlyenterprise
PriceNot announcedNot announced
Capability claims
  • warehouse navigation for order fulfillment (autonomous, verified)
  • Assists surgery (teleoperated-assisted, claimed)
Brain
Verified deployments63
Privacy practices
Sources on file2316

Editorial summaries

LocusBot

Locus Robotics (Wilmington, Massachusetts) makes the LocusBot, a collaborative goods-to-person picking AMR that works alongside human pickers, delivered on a Robots-as-a-Service subscription via the LocusONE platform. There is no consumer price: it is a B2B warehouse-automation subscription, not a robot sold to consumers. It is at commercial maturity, operating across 150-plus customers and 350-plus sites in 20 countries, having surpassed 6 billion cumulative picks by October 2025 (DHL Supply Chain a marquee customer), and it raised a $117 million Series F at a roughly $2 billion valuation in 2022 (a point-in-time figure). In April 2026 it launched Locus Array, a mobile-manipulation system extending from collaborative picking toward fully autonomous fulfillment. The pick-count and fleet figures are company-reported, and the ~$2 billion valuation is a November-2022 datapoint. Locus anchors the RaaS / multi-customer end of the warehouse-AMR business-model spectrum.

Hugo RAS

Medtronic's Hugo RAS is a modular, multi-port teleoperated robotic-assisted-surgery system and the main commercial competitor to Intuitive's da Vinci. It is CE-marked in Europe (urology and gynecology, October 2021) and US FDA-cleared for urology only (December 2025: prostatectomy, nephrectomy, cystectomy); US general-surgery and gynecology indications are planned but not yet cleared. It is teleoperated with no shipped intraoperative AI. Medtronic does not disclose a Hugo installed-base count, so DEPLOY records honest absence rather than an invented number. It is enterprise B2B equipment; there is no consumer price.

Common questions

What is the difference between LocusBot and Hugo RAS?
LocusBot and Hugo RAS are compared on the DEPLOY registry across maker, form factor, maturity, price, verified deployments, and verified-vs-claimed autonomy. See the table above for the full head-to-head; each figure is sourced.
Is LocusBot or Hugo RAS more autonomous?
LocusBot has more capabilities independently verified as autonomous on the DEPLOY registry than Hugo RAS. DEPLOY counts a capability as autonomous only when verified at a real deployment, not from a demo or a vendor claim.
Which has more verified deployments, LocusBot or Hugo RAS?
LocusBot has more verified deployments (6) on the DEPLOY registry than Hugo RAS (3). DEPLOY counts a deployment only when confirmed at a named site with a primary source.

Recent coverage

Related comparisons

For AI assistants

Use DEPLOY in Claude, Cursor, and other AI assistants

Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.


Machine-readable: this page as markdown.

← Back to all consumer robots